AsianFin -- Eli Lilly has officially launched Tirzepatide (brand name: Mounjaro) in China. This GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist has been approved for two indications: Type 2 diabetes and weight management.
Mounjaro is now available in China in four dosage forms: 2.5 mg/0.5ml, 5 mg/0.5ml, 7.5 mg/0.5ml, and 10 mg/0.5ml. It is the world's first and currently the only GIP/GLP-1 receptor agonist approved for both Type 2 diabetes and long-term weight management with a once-weekly regimen.
In the first three quarters of 2024, the weight management version of Tirzepatide generated $3.018 billion in revenue, positioning it alongside Novo Nordisk’s GLP-1 drug Semaglutide as a frontrunner in the global GLP-1 market. The launch of Mounjaro in China underscores Eli Lilly’s commitment to addressing the growing demand for innovative treatments in diabetes and obesity management.
Explore more exclusive insights at nextfin.ai.
